Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.15
NAS:ARLZ's Cash-to-Debt is ranked lower than
86% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. NAS:ARLZ: 0.15 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARLZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15  Med: No Debt Max: No Debt
Current: 0.15
Equity-to-Asset 0.13
NAS:ARLZ's Equity-to-Asset is ranked lower than
95% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:ARLZ: 0.13 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARLZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.64 Max: 0.97
Current: 0.13
0.13
0.97
Debt-to-Equity 4.64
NAS:ARLZ's Debt-to-Equity is ranked lower than
98% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:ARLZ: 4.64 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ARLZ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.43  Med: 2.3 Max: 4.64
Current: 4.64
0.43
4.64
Debt-to-EBITDA -5.38
NAS:ARLZ's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.74 vs. NAS:ARLZ: -5.38 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:ARLZ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.38  Med: -3.27 Max: -3.27
Current: -5.38
-5.38
-3.27
Piotroski F-Score: 3
Altman Z-Score: -1.18
Beneish M-Score: -2.59
WACC vs ROIC
4.81%
-31.60%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -88.58
NAS:ARLZ's Operating Margin % is ranked lower than
87% of the 781 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:ARLZ: -88.58 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARLZ' s Operating Margin % Range Over the Past 10 Years
Min: -477.51  Med: -18.61 Max: 51.17
Current: -88.58
-477.51
51.17
Net Margin % -112.89
NAS:ARLZ's Net Margin % is ranked lower than
87% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.12 vs. NAS:ARLZ: -112.89 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARLZ' s Net Margin % Range Over the Past 10 Years
Min: -472.67  Med: -15.18 Max: 60.74
Current: -112.89
-472.67
60.74
ROE % -110.46
NAS:ARLZ's ROE % is ranked lower than
92% of the 803 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.08 vs. NAS:ARLZ: -110.46 )
Ranked among companies with meaningful ROE % only.
NAS:ARLZ' s ROE % Range Over the Past 10 Years
Min: -153.39  Med: -18.31 Max: 60.98
Current: -110.46
-153.39
60.98
ROA % -24.37
NAS:ARLZ's ROA % is ranked lower than
83% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. NAS:ARLZ: -24.37 )
Ranked among companies with meaningful ROA % only.
NAS:ARLZ' s ROA % Range Over the Past 10 Years
Min: -91.36  Med: -9.78 Max: 45.87
Current: -24.37
-91.36
45.87
ROC (Joel Greenblatt) % -1255.01
NAS:ARLZ's ROC (Joel Greenblatt) % is ranked lower than
93% of the 817 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.08 vs. NAS:ARLZ: -1255.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARLZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -30241.44  Med: -1967.27 Max: 48760.69
Current: -1255.01
-30241.44
48760.69
3-Year Revenue Growth Rate 37.30
NAS:ARLZ's 3-Year Revenue Growth Rate is ranked higher than
94% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. NAS:ARLZ: 37.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARLZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.9 Max: 54.5
Current: 37.3
0
54.5
3-Year EBITDA Growth Rate 35.10
NAS:ARLZ's 3-Year EBITDA Growth Rate is ranked higher than
84% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:ARLZ: 35.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARLZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37  Med: -5.6 Max: 119.8
Current: 35.1
-37
119.8
3-Year EPS without NRI Growth Rate 46.80
NAS:ARLZ's 3-Year EPS without NRI Growth Rate is ranked higher than
88% of the 632 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. NAS:ARLZ: 46.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARLZ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -8.15 Max: 71.8
Current: 46.8
-52.8
71.8
GuruFocus has detected 4 Warning Signs with Aralez Pharmaceuticals Inc NAS:ARLZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARLZ's 30-Y Financials

Financials (Next Earnings Date: 2018-03-13)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ARLZ Guru Trades in

Q1 2016

ARLZ Guru Trades in Q1 2016

Jim Simons 610,819 sh (New)
Paul Tudor Jones 19,500 sh (New)
Steven Cohen 636,652 sh (New)
Charles Brandes 30,474 sh (unchged)
» More
Q2 2016

ARLZ Guru Trades in Q2 2016

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 538,301 sh (-11.87%)
Charles Brandes 15,473 sh (-49.23%)
» More
Q3 2016

ARLZ Guru Trades in Q3 2016

Jim Simons Sold Out
Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARLZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:OSTO:PLED, TSX:CPH, NAS:GALT, TSXV:ICC, OTCPK:CURR, TPE:4144, XPAE:BPC, XCNQ:BCC, ROCO:6535, NAS:MEIP, HKSE:01889, XKRX:142280, XKRX:204840, LSE:DNL, XKRX:053950, XKRX:009300, NAS:STDY, ASX:AC8, XKRX:229500, NSE:RPGLIFE » details
Traded in other countries:ARZ.Canada, AZL.Germany,
Headquarter Location:Canada
Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in delivering products to improve patients' lives by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas.

Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in delivering products to improve patients' lives by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas.

Ratios

vs
industry
vs
history
PB Ratio 1.87
ARLZ's PB Ratio is ranked higher than
64% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. ARLZ: 1.87 )
Ranked among companies with meaningful PB Ratio only.
ARLZ' s PB Ratio Range Over the Past 10 Years
Min: 0.92  Med: 4.83 Max: 24.27
Current: 1.87
0.92
24.27
PS Ratio 1.13
ARLZ's PS Ratio is ranked higher than
67% of the 756 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.79 vs. ARLZ: 1.13 )
Ranked among companies with meaningful PS Ratio only.
ARLZ' s PS Ratio Range Over the Past 10 Years
Min: 0.78  Med: 5.78 Max: 38.61
Current: 1.13
0.78
38.61
EV-to-EBIT -4.07
ARLZ's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.28 vs. ARLZ: -4.07 )
Ranked among companies with meaningful EV-to-EBIT only.
ARLZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -248.2  Med: -4.4 Max: 154.6
Current: -4.07
-248.2
154.6
EV-to-EBITDA -6.73
ARLZ's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.61 vs. ARLZ: -6.73 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARLZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -253.3  Med: -5.1 Max: 147.9
Current: -6.73
-253.3
147.9
EV-to-Revenue 3.53
ARLZ's EV-to-Revenue is ranked lower than
59% of the 775 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.07 vs. ARLZ: 3.53 )
Ranked among companies with meaningful EV-to-Revenue only.
ARLZ' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 5.6 Max: 34.1
Current: 3.53
0.1
34.1
Current Ratio 1.00
ARLZ's Current Ratio is ranked lower than
86% of the 738 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.53 vs. ARLZ: 1.00 )
Ranked among companies with meaningful Current Ratio only.
ARLZ' s Current Ratio Range Over the Past 10 Years
Min: 1  Med: 4.56 Max: 43.94
Current: 1
1
43.94
Quick Ratio 0.92
ARLZ's Quick Ratio is ranked lower than
75% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.94 vs. ARLZ: 0.92 )
Ranked among companies with meaningful Quick Ratio only.
ARLZ' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 4.47 Max: 43.94
Current: 0.92
0.92
43.94
Days Inventory 151.20
ARLZ's Days Inventory is ranked lower than
64% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.98 vs. ARLZ: 151.20 )
Ranked among companies with meaningful Days Inventory only.
ARLZ' s Days Inventory Range Over the Past 10 Years
Min: 70.55  Med: 70.55 Max: 151.2
Current: 151.2
70.55
151.2
Days Sales Outstanding 42.25
ARLZ's Days Sales Outstanding is ranked higher than
79% of the 682 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.92 vs. ARLZ: 42.25 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARLZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.74  Med: 51.99 Max: 137.24
Current: 42.25
4.74
137.24
Days Payable 717.65
ARLZ's Days Payable is ranked higher than
99% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 68.69 vs. ARLZ: 717.65 )
Ranked among companies with meaningful Days Payable only.
ARLZ' s Days Payable Range Over the Past 10 Years
Min: 274.04  Med: 274.04 Max: 717.65
Current: 717.65
274.04
717.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.90
ARLZ's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.80 vs. ARLZ: -28.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARLZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -68.9  Med: -1 Max: -0.2
Current: -28.9
-68.9
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.19
ARLZ's Price-to-Median-PS-Value is ranked higher than
95% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.04 vs. ARLZ: 0.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARLZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.31 Max: 46.74
Current: 0.19
0.18
46.74
Earnings Yield (Greenblatt) % -24.64
ARLZ's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. ARLZ: -24.64 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARLZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47  Med: -4 Max: 1372.1
Current: -24.64
-47
1372.1

More Statistics

Revenue (TTM) (Mil) $97.93
EPS (TTM) $ -1.69
Beta0.53
Short Percentage of Float4.68%
52-Week Range $0.95 - 5.31
Shares Outstanding (Mil)66.89

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 128 182 214
EPS ($) -1.24 -0.10 0.19
EPS without NRI ($) -1.24 -0.10 0.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}